Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial
Name:
mdz247.158.pdf
Size:
84.75Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract
Authors
Abou-Alfa, GKBorbath, I
Clarke, SJ
Hitre, E
Louvet, C
Macarulla, T
Oh, DY
Spratlin, JL
Valle, Juan W
Weiss, KH
Berman, C
Howland, M
Ye, Y
Cho, T
Moran, S
Javle, MM
Affiliation
Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NYIssue Date
2019
Metadata
Show full item recordCitation
Abou-Alfa GK, Borbath I, Clarke SJ, Hitre E, Louvet C, Macarulla T, et al. 832TiP Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial. Annals of Oncology. 2019;30(Supplement_5).Journal
Annals of OncologyDOI
10.1093/annonc/mdz247.158Additional Links
https://dx.doi.org/10.1093/annonc/mdz247.158Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz247.158